Introduction
The European population was stable for many years, and demographic projections expect a similar trend for the years to come. However, the ageing of population leads to an increase in overall cancer incidence. This holds true for prostate cancer, which has increased across Europe over the last two decades [1] , and is predicted to continue to grow [2] . Around 10-20% of patients with prostate cancer are diagnosed at an advanced stage, and >40% of men diagnosed with prostate cancer will eventually develop advanced disease [3, 4] . The 5-year prostate cancer survival rates in Europe have improved over the last 20 years. However, prognosis still varies widely from country to country with 5-year survival rates ranging from 47.7% to 83.3% [5] .
There is a need for new medicines that target prostate cancer differently, providing alternative therapeutic options for patients at late stages of their disease [3] . The treatment of advanced prostate cancer is entering a new era with innovative therapies, being recently approved and/or in clinical development, that have the potential to improve patient outcomes and quality of life in future. However, patients with castration-resistant prostate cancer (CRPC) currently have few treatment options [4] . Reduced or delayed access to new cancer drugs is considered to have an impact on patients' survival [6] .
Several new treatments of CRPC have successfully completed phase III trials, and have received regulatory approval. These studies showed a significant improvement in overall survival (OS), taking into account hazard ratio (HR) considered as the best indicator of OS, and also reported improved or preserved quality of life (QoL).
Innovative cancer therapies and advances in drug development have created new hopes for patients and health providers, but also contribute to an increase in health expenditures in an already costconscious environment. Over the last decades, the therapeutic innovation for cancer therapy had to deal with two issues that are closely linked: the treatment access for the majority of patients, and the cost of treatments. In efforts to manage healthcare and/or hospital and drug costs, healthcare policy-and decision-makers may seek to delay or restrict access to new innovative drugs. Such actions have a real impact on survival rates of patients [6] .
The European countries implemented various processes to answer these questions leading to a heterogeneous access to cancer drugs. The answers are based on the evaluation of the benefit/risk ratio of drugs, followed by a price-trading depending on the country. More and more, the time to market access is extended, according to the country, mainly because of a price-trading prolongation between payers and pharmaceutical companies. Several years after the approval of new cancer drugs, some countries may still have a wide nontreated population. This represents a substantial loss for patients. Paradoxically, the wish expressed by most of the health care authorities is to allow a fast access to the therapeutic innovation. Beside financial challenge, the payers have to face ethical requirements favoring an appropriate and equivalent health care access for each patient within the frame of a limited budget.
The purpose of this article, on the basis of detailed examples in metastatic CRPC (mCRPC), is to describe difficulties and discrepancies regarding a quick provision to therapeutic innovations to the patients.
Methods
The primary objective of this article was to evaluate the discrepancies in the assessment of the magnitude of benefit of four new drugs with distinct mechanisms of action: novel androgen receptor pathway inhibitors (abiraterone acetate, enzalutamide), taxane (cabazitaxel), and a bonetargeting alpha-emitting radionuclide (radium-223 dichloride) for the treatment of mCRPC. The comparison was done among three European countries (UK, Germany and France) and Canada.
Moreover, the assigned value by the European Society of Medical Oncology Magnitude of Clinical Benefit Scale version 1 (ESMO-MCBS v1.0) was compared to the statement of each country [7] . The ESMO-MCBS v1.0 used a standardized, objective and reproducible approach of the magnitude of benefit between studies that incorporate different primary outcomes (OS, progression-free survival [PFS], QoL), different designs through a process of variable weighting of primary outcomes, adjustments for significant secondary outcomes and toxicity. For new agents or approaches in the management of cancers without curative intent, the scale is graded from 5 to 1, where grades 5 and 4 represent a high level of proven clinical benefit.
Secondary objectives were the analysis of discrepancies between results of clinical trials and time to treatment access, and impact on reimbursement in those countries.
Specificities of national drug assessment among selected countries
The four selected countries used different systems to evaluate the interest of new drugs: National Institute for Health and Care Excellence (NICE) in UK, Gemeinsamer Bundesausschuss (G-BA) in Germany, Haute Autorité de Santé (HAS) in France and pan-Canadian Oncology Drug Review (pCODR) in Canada.
In contrast to the methods of healthcare evaluation in other countries, in UK, NICE does not evaluate all interventions when drugs reach the market. Health technologies can be appraised by NICE through two methods: multiple technology appraisals (MTA) examining a disease area or a class of drugs, and single technology appraisal (STA) developed to provide early guidance for new drugs targeting a single indication. The NICE reporting is mainly based on the cost-effectiveness of drugs. For instance, in February 2012, NICE recommended against the use of abiraterone acetate in combination with corticosteroids due to the high cost of therapy [8] . However, this original decision was reversed in May 2012 when the manufacturer revised its patient access scheme to allow for discounting of National Health Service's (NHS) cost for the drug through a risk-sharing agreement [9] .
In Germany, one of the largest pharmaceutical markets worldwide, the Act on the Reform of the Market for Medicinal Products (Arzneimittelmarkt-Neuordnungsgesetz-AMNOG) was enacted in 2011 and mandates a more rigorous benefit evaluation procedure for new pharmaceuticals, thereby adding challenges to the market access process. In AMNOG's new system, manufacturers continue to set the initial price for new prescription drugs after regulatory approval. This price is valid for 1 year. During this time, the manufacturer's value dossier is reviewed by the G-BA, which determines the level of added benefit of this new drug relative to the appropriate comparative therapy.
In France, approved pharmaceuticals are subjected to a technical assessment by the 'High Healthcare Authority' (HAS), which hosts the 'Transparency Commission' appraising a 'Medical Benefit' level (SMR), and an ASMR level using a scale ranging from 1 to 5 according to the therapeutic improvement provided by a new drug
. Based on this evaluation, drugs are enlisted with a fixed price, and reimbursement rate. Additionally, hospital drugs can be listed on two additional lists: hospital drugs delivered to outpatients and hospital only costly drugs that are charged to health insurance in addition to hospital stay fees. Those in-patients drugs are covered by 'homogeneous group of patients' (GHM), which corresponds to a homogeneous group of hospital stay (GHS), and correlated to care activities. This system allows defining a maximal pricing for each GHM/GHS entity. However, an additional list allows guaranteeing the financing of innovative and expensive treatments to provide the access to those treatments, and to take into account discrepancies between GHM and specific diseases.
Canada presents with a unique and challenging pathway to market access. A report found 46 federal, provincial and territorial drug programs for the Canadian public sector, each having its own administration, bureaucracy, timelines and priorities [10] . In addition, individual hospitals are responsible for developing their own formularies for governmentfunded drugs administered to patients on an in-patient basis. Finally, private payers are responsible for making drug coverage and pricing decisions for their members. This mosaic of entities has created hurdles in the form of market access delays and uncertainty on how different bodies evaluate product value. To harmonize funding decisions across jurisdictions, the Common Drug Review (CDR) and the more recently established pCODR are tasked with performing Health Technology Assessment, and with providing recommendations to province and territory drug programs.
Results of pivotal clinical trials
The four drugs (abiraterone acetate, enzalutamide, cabazitaxel and radium-223 dichloride) were subjected to early access/compassionate use programs in the different countries. In France, for instance, individual patient's programs (individual 'temporary authorization for use' [TAU]), and cohort TAU were granted for all four drugs between 2010 and 2014. Those programs ceased once regulatory approvals were given. Interestingly, all of these drugs demonstrated a significant improvement in OS with a HR 0.70 (Table 1) .
Abiraterone acetate
Abiraterone acetate (AA), inhibitor of androgen biosynthesis, was registered by the European Medicines Agency (EMA) in September 2011 on the basis of the pivotal trial COU-AA-302. This study compared AA with placebo (both combined with prednisone) in chemo-naive mCRPC Industry corner Annals of Oncology patients, asymptomatic or mildly symptomatic. Intermediate and final results of this study showed that AA significantly improved radiologic PFS (rPFS) and OS (Table 1) [11, 12] . A previous phase III randomized trial, COU-AA-301, showed that AA improved OS in mCRPC patients progressing after docetaxel (Table 1 ) [13] . The most common grade 3-4 adverse events of special interest were cardiac disorders (8% versus 4%), increased in alanine aminotransferase (6% versus < 1%) and hypertension (5% versus 3%) [12] .
Enzalutamide
The results of the AFFIRM pivotal trial led to the registration of enzalutamide, an androgen receptor signaling inhibitor, by the EMA in June 2013. The AFFIRM trial compared enzalutamide with placebo in progressive mCRPC patients, previously treated with docetaxel. Enzalutamide significantly prolonged survival (Table 1) , with higher rates of fatigue, diarrhea and hot flashes compared to placebo [14] . Thereafter, the PREVAIL trial compared enzalutamide with placebo in chemo-naive mCRPC patients, showing that enzalutamide significantly decreased the risk of rPFS and death, and delayed the initiation of chemotherapy in men with metastatic prostate cancer (Table 1 ) [15] .
Cabazitaxel
Cabazitaxel is a new taxane, a microtubule inhibitor developed to overcome resistance to docetaxel. The pivotal TROPIC trial allowed the registration of cabazitaxel by the EMA in March 2011. In this study, cabazitaxel plus prednisone significantly prolonged OS versus mitoxantrone plus prednisone in mCRPC patients progressing during or after docetaxel therapy (Table 1 ) [16] . The most common clinically significant grade 3 or higher adverse events were neutropenia and diarrhea.
Radium-223 dichloride
Radium-223 is an alpha emitter, which selectively targets bone metastases. The pivotal ALSYMPCA trial led to the registration of radium-223 by EMA in November 2013. This trial compared radium-223 with placebo in men with mCRPC and at least two symptomatic bone metastases, and who had received previous docetaxel therapy or were unfit to docetaxel. The study showed that radium-223 significantly improved OS (Table 1) [17]. The effect of radium-223 on OS was irrespective of any previous use of docetaxel. Radium-223 was associated with low myelosuppression rates and, overall, an incidence of adverse events comparable to that in the placebo group.
Magnitude of benefit assessment between European countries
These four drugs (AA, enzalutamide, cabazitaxel and radium-223 dichloride) provide an improvement in OS [11] [12] [13] [14] [15] [16] [17] . All of them were centrally authorized by the EMA. For AA and enzalutamide, an extension of the indications was requested, and accepted by the EMA. Initially indicated in mCRPC after docetaxel, AA is now indicated in chemo-naive metastatic patients. Enzalutamide that was primarily indicated after docetaxel is now indicated in chemo-naive metastatic patients, as the result of the evaluation of data of a new pivotal clinical trial (PREVAIL), showing a significant improvement in OS for this population of mCRPC [15] .
Recently, the American Society of Clinical Oncology (ASCO) published a comparison of magnitude of clinical benefit, ranking cancer treatments through an independent assessment and a robust methodology [18] . Points are awarded (or subtracted) in the categories of clinical benefit and toxicity. In the advanced disease framework, bonus points can be earned if a regimen shows statistically improvement in palliation of symptoms-and/or treatment-free interval compared with the control treatment in a clinical trial. Clinical benefit and toxicity (and bonus points in the advanced disease framework) are combined to generate a net health benefit (NHB) score, which is then juxtaposed against the treatment cost, to provide an overall assessment.
In Table 2 , the magnitude benefit assessment is presented among the four selected countries (UK, Germany, France and Canada) according to their own assessment process. Moreover, the independent statements of ESMO and ASCO were added. Whereas those drugs are authorized by the EMA, one can observed that clear discrepancies in the magnitude of benefit assessment exist between selected countries, as well as between local health authorities and learned societies. Those discrepancies have a direct impact on the reimbursement conditions. Thereby, these heterogeneous administrative processes could significantly hinder the access to therapeutic innovation. 
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An example of discrepancies: radium-223 dichloride
From European approval of radium-223 until now, >2 years have elapsed.
From this time, a lot of patients could not benefit from the drug in countries like France, knowing that the predicted survival time from diagnosis of mCRPC is of 20 months according to nomograms [19] . For instance, several thousand of German patients have already been treated, whereas very few patients have received the drug in France, and in UK, radium-223 has only been approved after docetaxel use, which makes little clinical sense with regard to clinical results. This highlights the inequality in access to new cancer drugs, and how the treatment opportunity of European cancer patients depends where they live.
Regulatory status of radium-223 dichloride in the world
In 2013, the American Society of Clinical Oncology published its annual report on progress against cancer [20] . In this report, three treatments were considered as bringing a major progress in the management of cancer: ado-trastuzumab emtansine in metastatic breast cancer, nabpaclitaxel for metastatic pancreas cancer and radium-223 for CRPC with symptomatic bone metastases. Radium-223 received the approval from the Food and Drug Administration (FDA) in May 2013. This statement was followed by the approval of EMA in December 2013. In most of the European countries, radium-223 was fully reimbursed between 2013 and 2015. Until then, it was subject to special programs (early access programs, or TAU). European countries with no full reimbursement, and thereby limiting access to radium-223, are mainly those of the Eastern Europe, and France as described below. Among main countries of the European Union (EU), France remains the only country to freeze full reimbursement of radium-223. However, radium-223 was subject to a TAU program, meaning that the French health authorities recognized that radium-223 met a true medical need in spite of a minor level of ASMR (ASMR 4). Following the TAU period, the French health authorities associated radium-223 with a GHM. This classification of radium-223 led to a partial reimbursement of the drug, with a cost predominantly covered by local institutions.
Discussion
The EU imposed central marketing authorization for cancer drugs since 2005, aiming at obtaining efficiency and speed of the process for new pharmaceuticals [21] . The EMA grants a single marketing authorization for all European Union countries based on safety and efficacy of the drug. However, price setting and reimbursement decisions remain national responsibility with differences in assessment of the medical value of new treatment across countries, leading to a heterogeneous accessibility to cancer treatments [22, 23] . In the light of these multiple pitfalls, the MBCS was developed by the ESMO to highlight treatments which bring substantial improvements to the duration of survival and/ or the QoL of cancer patients, and to accelerate reimbursement evaluation [7] .
This article illustrates the consequences of the European approval and reimbursement procedures for cancer therapy. Indeed, we observed a huge discrepancy between the evaluation of two major learned societies, ESMO and ASCO guidelines that provided quite similar conclusions [7, 18] , and that of European health authorities. If Germany and Canada matched with ESMO and ASCO evaluations, one can state that France, considered as a 'major' country, has a different way of evaluation, leading to conclusions that are not in agreement with the international recommendations in terms of efficacy assessment and access to treatments.
Nevertheless, during the last decades, the development of new treatments for mCRPC allowed a step-by-step increase in median survival, ranging from 6 to 10 months in the 1990s to 20 months in 2010 according to nomograms, to reach 32 months for patients [19, 24] . Those results should be considered as cost-effective. Cost-effectiveness is one factor used for decisions on reimbursement in some countries. How to improve the cost-effectiveness of new drugs? One way could be to improve the design of clinical trials. Currently, clinical trial data are produced to evaluate the use of the new drug therapy and extrapolate its utilization in the long term. Payers do express uncertainty, however regarding the routine use and the future potential of these new drugs before they have been introduced in the market. One could argue that real life data remains more efficient than clinical trials data, supporting TAU and post-marketing survey processes. As health care costs are constantly rising and governments are reforming their healthcare systems, there is an urgent need to reshape the European clinical research landscape. Meaningful data for reimbursement strategies will be a major goal of future clinical trials. Strategies ensuring that we can gather robust and relevant data about the effectiveness of various healthcare interventions have to be developed to provide optimal patient's care within the limits of a healthcare budget [25] . Another challenge is those of European countries with limited resources, such as Eastern Europe countries. In such countries, there is a need for adapted clinical study endpoints, and innovative models of collaboration between for-profit and nonprofit organizations [26] . Although cancer is a huge concern in the frame of European healthcare policy, one could notice that the patchwork of European benefit/risk assessment leads to conflicting conclusions. The challenges are based on a greater understanding of the barriers facing drug developers and several sets of recommendations to optimize patients' access to innovative, safe, effective and fairly priced cancer treatments [27] .
In summary, several procedures have to be implemented to overcome the patchwork of administrative assessments. Among them, the trading price should be based on independent statements of learned societies. Besides, governments reduce drug expenditure by limiting the pricing/volume equation, i.e. by limiting the reimbursement and by limiting the volume using a favorable labeling. An early market access of cancer drugs, considered as priority medicines, could be developed by using new procedures such as conditional marketing authorization as currently proposed by the EMA [28] . Overall, we have to find a balance between cost of care and cost-efficiency.
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